Water-soluble fullerene (C60) inhibits the osteoclast differentiation and bone destruction in arthritis.
Recently, it has been demonstrated that oxygen free radicals have an important role as a signaling messenger in the receptor activator NFkappaB (RANK) signal pathway required for osteoclast differentiation. The aim of this study was to examine the potential of a strong free-radical scavenger, water-soluble fullerene (C60), as a protective agent against the RANK-induced osteoclastogenesis and osteoclastic bone destruction in arthritis, both in vitro and in vivo. The effects of C60 on the RANK-induced osteoclastogenesis and osteoclastic bone resorption were examined in vitro. Adjuvant-induced arthritic rats were used as an animal model of arthritis. Rats were divided into two subgroups: control and treatment with C60 at 1.0 microM. The left ankle joint was injected intra-articularly with water-soluble C60 (20 microl) in the C60-treated group, while, as a control, the left ankle joint in the control rats received phosphate-buffered saline (20 microl) once weekly for eight weeks. Ankle joint tissues were prepared for histologic analysis. C60 significantly inhibited the responses of osteoclast precursor cells to RANK ligand, including osteoclast differentiation and osteoclastic bone resorption in vitro. In adjuvant-induced arthritic rats, intra-articular treatment with C60 in vivo reduced the number of osteoclasts and alleviated bone resorption and destruction in the joints, while control ankle joints showed progression of joint destruction with time. These findings indicate that C60 downregulates the RANK-induced osteoclast differentiation and is a potential therapeutic agent for inhibition of osteoclastic bone destruction in arthritis.
Yudoh
Kazuo
K
Department of Frontier Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki City 216-8512, Japan. yudo@marianna-u.ac.jp
Karasawa
Rie
R
Masuko
Kayo
K
Kato
Tomohiro
T
D000818:Animals; D001169:Arthritis, Experimental / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control*; D001862:Bone Resorption / Q000473:pathology* / Q000517:prevention & control*; D002454:Cell Differentiation; D002478:Cells, Cultured; D003804:Dentin / Q000187:drug effects / Q000473:pathology; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage; D037741:Fullerenes / Q000008:administration & dosage*; D006801:Humans; D066298:In Vitro Techniques; D050997:Nanomedicine; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology*; D053245:RANK Ligand / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D012995:Solubility; D014867:Water
D016166:Free Radical Scavengers; D037741:Fullerenes; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D014867:Water; C069837:fullerene C60